EULAR Sj?gren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

摘要

Rituximab therapy is a promising treatment for primary Sjogren's syndrome (pSS). So far, treatment studies performed in patients with pSS lacked the use of a uniform outcome measure to monitor disease activity. Recently, the European League Against Rheumatism (EULAR) developed the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI). ESSDAI was shown to be able to monitor disease activity in patient profile and open-label studies. To further study the utility of ESSDAI for clinical studies, we assessed the responsiveness of ESSDAI after rituximab treatment in a randomised controlled trial (RCT) of patients with pSS.